{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:23:26Z","timestamp":1782221006057,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00467-022-05637-8","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T10:02:59Z","timestamp":1660557779000},"page":"1127-1138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome"],"prefix":"10.1007","volume":"38","author":[{"given":"Tracy E.","family":"Hunley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kar Hui","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hostensia M.","family":"Beng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoshi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Smoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"key":"5637_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R (2018) Idiopathic nephrotic syndrome in children. Lancet 392:61\u201374","journal-title":"Lancet"},{"key":"5637_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pcl.2018.08.006","volume":"66","author":"CS Wang","year":"2019","unstructured":"Wang CS, Greenbaum LA (2019) Nephrotic syndrome. Pediatr Clin North Am 66:73\u201385","journal-title":"Pediatr Clin North Am"},{"key":"5637_CR3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jpeds.2004.08.022","volume":"145","author":"EM Ruth","year":"2004","unstructured":"Ruth EM, Landolt MA, Neuhaus TJ, Kemper MJ (2004) Health-related quality of life and psychosocial adjustment in steroid-sensitive nephrotic syndrome. J Pediatr 145:778\u2013783","journal-title":"J Pediatr"},{"key":"5637_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.kint.2020.11.013","volume":"99","author":"DS Gipson","year":"2001","unstructured":"Gipson DS, Tarnoff J, Lee L et al (2001) A pediatric gateway initiative for glomerular disease: introducing PIONEER. Kidney Int 99:515\u2013518","journal-title":"Kidney Int"},{"key":"5637_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.kint.2020.09.038","volume":"99","author":"L Barisoni","year":"2021","unstructured":"Barisoni L, Barratt J, Campbell K et al (2021) Innovating and invigorating the clinical trial infrastructure for glomerular diseases. Kidney Int 99:519\u2013523","journal-title":"Kidney Int"},{"key":"5637_CR6","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2337\/diacare.14.11.1083","volume":"14","author":"Y Iwamoto","year":"1994","unstructured":"Iwamoto Y, Kuzuya T, Matsuda A et al (1994) Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14:1083\u20131086","journal-title":"Diabetes Care"},{"key":"5637_CR7","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1056\/NEJM199411033311803","volume":"331","author":"JJ Nolan","year":"1994","unstructured":"Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188\u20131193","journal-title":"N Engl J Med"},{"key":"5637_CR8","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1056-8727(00)00124-0","volume":"14","author":"T Nakamura","year":"2000","unstructured":"Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H (2000) Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 14:250\u2013254","journal-title":"J Diabetes Complications"},{"key":"5637_CR9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1053\/j.ajkd.2009.11.013","volume":"55","author":"PA Sarafidis","year":"2010","unstructured":"Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN (2010) Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 55:835\u2013847","journal-title":"Am J Kidney Dis"},{"key":"5637_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1440-1797.2007.00903.x","volume":"13","author":"P Kincaid-Smith","year":"2008","unstructured":"Kincaid-Smith P, Fairley KF, Farish S, Best JD, Proietto J (2008) Reduction of proteinuria by rosiglitazone in non-diabetic renal disease. Nephrology (Carlton) 13:58\u201362","journal-title":"Nephrology (Carlton)"},{"key":"5637_CR11","first-page":"1459","volume":"16","author":"S Shahidi","year":"2011","unstructured":"Shahidi S, Pakzad B, Mortazavi M et al (2011) Reduction of proteinuria by pioglitazone in patients with non-diabetic renal disease. J Res Med Sci 16:1459\u20131465","journal-title":"J Res Med Sci"},{"key":"5637_CR12","doi-asserted-by":"publisher","first-page":"108620","DOI":"10.1016\/j.diabres.2020.108620","volume":"172","author":"A Sharma","year":"2020","unstructured":"Sharma A, Bourey RE, Edwards JC, Brink DS, Albert SG (2020) Nephrotic range proteinuria associated with focal segmental glomerulosclerosis reversed with pioglitazone therapy in a patient with Dunnigan type lipodystrophy. Diabetes Res Clin Pract 172:108620","journal-title":"Diabetes Res Clin Pract"},{"key":"5637_CR13","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/sj.ki.5002248","volume":"71","author":"T Kanjanabuch","year":"2007","unstructured":"Kanjanabuch T, Ma LJ, Chen J et al (2007) PPAR-gamma agonist protects podocytes from injury. Kidney Int 71:1232\u20131239","journal-title":"Kidney Int"},{"key":"5637_CR14","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1681\/ASN.2005090983","volume":"17","author":"A Benigni","year":"2006","unstructured":"Benigni A, Zoja C, Tomasoni S et al (2006) Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol 17:1624\u20131632","journal-title":"J Am Soc Nephrol"},{"key":"5637_CR15","doi-asserted-by":"publisher","first-page":"24392","DOI":"10.1038\/srep24392","volume":"6","author":"S Agrawal","year":"2016","unstructured":"Agrawal S, Chanley MA, Westbrook D et al (2016) Pioglitazone enhances the beneficial effects of glucocorticoids in experimental nephrotic syndrome. Sci Rep 6:24392","journal-title":"Sci Rep"},{"key":"5637_CR16","first-page":"423","volume":"32","author":"C Platt","year":"2017","unstructured":"Platt C, Coward RJ (2017) Peroxisome proliferator activating receptor-gamma and the podocyte. Nephrol Dial Transplant 32:423\u2013433","journal-title":"Nephrol Dial Transplant"},{"key":"5637_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1124\/mol.111.071654","volume":"80","author":"S Agrawal","year":"2011","unstructured":"Agrawal S, Guess AJ, Benndorf R, Smoyer WE (2011) Comparison of direct action of thiazolidinediones and glucocorticoids on renal podocytes: protection from injury and molecular effects. Mol Pharmacol 80:389\u2013399","journal-title":"Mol Pharmacol"},{"key":"5637_CR18","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1681\/ASN.2015080885","volume":"28","author":"R Sonneveld","year":"2017","unstructured":"Sonneveld R, Hoenderop JG, Isidori AM et al (2017) Sildenafil prevents podocyte injury via PPAR-gamma-mediated TRPC6 inhibition. J Am Soc Nephrol 28:1491\u20131505","journal-title":"J Am Soc Nephrol"},{"key":"5637_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Munoz A, Schneider MF et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637","journal-title":"J Am Soc Nephrol"},{"key":"5637_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.kint.2018.01.034","volume":"94","author":"DK Ng","year":"2018","unstructured":"Ng DK, Schwartz GJ, Schneider MF, Furth SL, Warady BA (2018) Combination of pediatric and adult formulas yield valid glomerular filtration rate estimates in young adults with a history of pediatric chronic kidney disease. Kidney Int 94:170\u2013177","journal-title":"Kidney Int"},{"key":"5637_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612","journal-title":"Ann Intern Med"},{"key":"5637_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nm.3159","volume":"19","author":"M Ahmadian","year":"2013","unstructured":"Ahmadian M, Suh JM, Hah N et al (2013) PPAR\u03b3 signaling and metabolism: the good, the bad and the future. Nat Med 19:557\u2013566","journal-title":"Nat Med"},{"key":"5637_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2337\/diacare.27.1.256","volume":"27","author":"RW Nesto","year":"2004","unstructured":"Nesto RW, Bell D, Bonow RO et al (2004) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27:256\u2013263","journal-title":"Diabetes Care"},{"key":"5637_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1046\/j.1523-1755.2001.00766.x","volume":"60","author":"Y Guan","year":"2001","unstructured":"Guan Y, Breyer MD (2001) Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 60:14\u201330","journal-title":"Kidney Int"},{"key":"5637_CR25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1046\/j.1464-5491.2001.00463.x","volume":"18","author":"T Nakamura","year":"2001","unstructured":"Nakamura T, Ushiyama C, Suzuki S et al (2001) Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 18:308\u2013313","journal-title":"Diabet Med"},{"key":"5637_CR26","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/sj.ki.5001620","volume":"70","author":"PA Sarafidis","year":"2006","unstructured":"Sarafidis PA, Bakris GL (2006) Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 70:1223\u20131233","journal-title":"Kidney Int"},{"key":"5637_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.dsx.2018.04.013","volume":"13","author":"P Pourshabanan","year":"2019","unstructured":"Pourshabanan P, Momeni A, Mahmoudnia L, Kheiri S (2019) Effect of pioglitazone on decreasing of proteinuria in type 2 diabetic patients with nephropathy. Diabetes Metab Syndr 13:132\u2013136","journal-title":"Diabetes Metab Syndr"},{"key":"5637_CR28","doi-asserted-by":"publisher","first-page":"dgz252","DOI":"10.1210\/clinem\/dgz252","volume":"105","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Huang Y, Ji X, Wang X, Shen L, Wang Y (2020) Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis. J Clin Endocrinol Metab 105:dgz252","journal-title":"J Clin Endocrinol Metab"},{"key":"5637_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2215\/CJN.02310508","volume":"4","author":"MS Joy","year":"2009","unstructured":"Joy MS, Gipson DS, Dike M et al (2009) Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol 4:39\u201347","journal-title":"Clin J Am Soc Nephrol"},{"key":"5637_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1440-1797.2009.01146.x","volume":"15","author":"HF Liu","year":"2010","unstructured":"Liu HF, Guo LQ, Huang YY et al (2010) Thiazolidinedione attenuate proteinuria and glomerulosclerosis in adriamycin-induced nephropathy rats via slit diaphragm protection. Nephrology (Carlton) 15:75\u201383","journal-title":"Nephrology (Carlton)"},{"key":"5637_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1476-5381.2010.01032.x","volume":"162","author":"G Miglio","year":"2011","unstructured":"Miglio G, Rosa AC, Rattazzi L et al (2011) The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury. Br J Pharmacol 162:111\u2013125","journal-title":"Br J Pharmacol"},{"key":"5637_CR32","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1053\/meta.2001.26703","volume":"50","author":"T Nakamura","year":"2001","unstructured":"Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H (2001) Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 50:1193\u20131196","journal-title":"Metabolism"},{"key":"5637_CR33","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1681\/ASN.20203110S1617c","volume":"31","author":"SAS Bhayana","year":"2020","unstructured":"Bhayana SAS, Chanley MA, Waller AP, Wolfgang KJ, Wijeratne S, Fitch J, White P, Kerlin BA, Smoyer WE (2020) Glomerular transcriptomic analysis of glucocorticoid- and pioglitazone-treated nephrotic syndrome. J Am Soc Nephrol 31:617","journal-title":"J Am Soc Nephrol"},{"key":"5637_CR34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41581-020-00339-6","volume":"17","author":"S Agrawal","year":"2021","unstructured":"Agrawal S, He JC, Tharaux PL (2021) Nuclear receptors in podocyte biology and glomerular disease. Nat Rev Nephrol 17:185\u2013204","journal-title":"Nat Rev Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05637-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-022-05637-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05637-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T19:08:46Z","timestamp":1727809726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-022-05637-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["5637"],"URL":"https:\/\/doi.org\/10.1007\/s00467-022-05637-8","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"assertion":[{"value":"21 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TEH, GH, KHN, YS, KM, HMB, QW, and MH have no financial interests. WES is a co-founder of NephKey Therapeutics, Inc., and is on the Board of Directors of NephCure Kidney International and receives no compensation as a member of the Board of Directors. TEH is on the Editorial Board of Frontiers in Pediatrics and receives no compensation as a member of the Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}